APLS
Price:
$41.03
Market Cap:
$5.25B
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical evaluation. This advanced-stage therapy is being explored for its potential in treating geographic atrophy (GA), a form of age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH). Beyond this lead candidate, Apellis also offers EMPAVELI (a systemic formulation of pegcetacoplan), w...[Read more]
Industry
Biotechnology
IPO Date
2017-11-09
Stock Exchange
NASDAQ
Ticker
APLS
According to Apellis Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 38.35. This represents a change of 241.75% compared to the average of 11.22 of the last 4 quarters.
The mean historical PE Ratio of Apellis Pharmaceuticals, Inc. over the last ten years is 4.60. The current 38.35 PE Ratio has changed 83.34% with respect to the historical average. Over the past ten years (40 quarters), APLS's PE Ratio was at its highest in in the March 2026 quarter at 67.94. The PE Ratio was at its lowest in in the June 2024 quarter at -29.85.
Average
4.60
Median
-8.89
Minimum
-19.98
Maximum
141.40
Discovering the peaks and valleys of Apellis Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 99.35%
Maximum Annual PE Ratio = 141.40
Minimum Annual Increase = -807.68%
Minimum Annual PE Ratio = -19.98
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | 141.40 | -807.68% |
| 2024 | -19.98 | 48.68% |
| 2023 | -13.44 | 59.72% |
| 2022 | -8.41 | 57.33% |
| 2021 | -5.35 | -57.10% |
| 2020 | -12.47 | 99.35% |
| 2019 | -6.25 | 11.13% |
| 2018 | -5.63 | -61.35% |
| 2017 | -14.56 | 55.58% |
| 2016 | -9.36 | 71.49% |
The current PE Ratio of Apellis Pharmaceuticals, Inc. (APLS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
35.99
5-year avg
18.84
10-year avg
4.60
Apellis Pharmaceuticals, Inc.’s PE Ratio is greater than Catalyst Pharmaceuticals, Inc. (17.32), less than Kiniksa Pharmaceuticals, Ltd. (54.35), greater than Mineralys Therapeutics, Inc. (-12.89), greater than Beam Therapeutics Inc. (-46.09), greater than Cidara Therapeutics, Inc. (-18.63), greater than Adaptive Biotechnologies Corporation (-55.10), greater than Scholar Rock Holding Corporation (-13.76), greater than IDEAYA Biosciences, Inc. (-18.35), greater than Agios Pharmaceuticals, Inc. (-4.10), greater than Recursion Pharmaceuticals, Inc. (-2.98),
| Company | PE Ratio | Market cap |
|---|---|---|
| 17.32 | $3.84B | |
| 54.35 | $3.90B | |
| -12.89 | $1.57B | |
| -46.09 | $2.99B | |
| -18.63 | $5.61B | |
| -55.10 | $2.82B | |
| -13.76 | $5.29B | |
| -18.35 | $2.74B | |
| -4.10 | $1.75B | |
| -2.98 | $1.41B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Apellis Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Apellis Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Apellis Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for Apellis Pharmaceuticals, Inc. (APLS)?
What is the highest PE Ratio for Apellis Pharmaceuticals, Inc. (APLS)?
What is the 3-year average PE Ratio for Apellis Pharmaceuticals, Inc. (APLS)?
What is the 5-year average PE Ratio for Apellis Pharmaceuticals, Inc. (APLS)?
How does the current PE Ratio for Apellis Pharmaceuticals, Inc. (APLS) compare to its historical average?